Amgen prevails in Epogen patent dispute with Hospira

An appeals court has affirmed a lower court verdict that Pfizer (PFE +2.7%) unit Hospira’s proposed Epogen biosimilar infringes on Amgen’s (AMGN +2.3%) U.S. Patent No. 5,856,298, upholding $70M in damages awarded in September 2017.

https://seekingalpha.com/news/3526465-amgen-prevails-in-epogen-patent-dispute-hospira